Ann: Positive final results from CAVATAK Phase 2 Melanoma Trial, page-2

Fantastic Results:

Viralytics Reports Positive Final Results from CAVATAKTM Phase 2 Melanoma Trial Presentation at American Society for Clinical Oncology Annual Meeting 2015


Primary endpoint achieved with 38.6% (22/57) of late-stage melanoma patients achieved the irPFS1 endpoint
 Objective response rate of 28% (16/57) with eight patients achieving complete response2
 Durable response3 persisting for at least 6 months in 21% of patients
 Activity in non-injected distant lesions, including lung and liver metastases
 One-year survival rate of 75.4% with median overall survival4 of 26 months
 Well tolerated in 57 patients - no grade 3 or 4 treatment-related adverse events5
 Exciting results from biopsy study point to combination synergy with checkpoint inhibitors